India Pharma Forum: What The FDA, Indian Regulator Flagged Up
Regulators Discuss Cross Contamination Risks, Quality Culture, ‘Filtered’ Harmonization
Executive Summary
The two-day India Pharmaceutical Forum in Mumbai highlighted key aspects of quality management and its challenges, trends on inspection outcomes in India and emerging concerns of 'dangerous cross contamination.'
You may also be interested in...
Quality Street: India Needs A Frances Kelsey, Many Of Her Kind
Scrip delves into some of India’s critical compliance and quality challenges and efforts to address those.
FDA’s McMullen: No Bigger Waste Than Drug Shortages Due To Data Integrity
FDA officials highlight at a recent summit in India recurring issues around drug manufacturing compliance including microbial contamination and data integrity concerns but emphasize that the agency isn’t in a “gotcha” mode for companies.
Responding To FDA 483s And Warning Letters: Some Dos, Don’ts And Red Flags
Invalidated OOS results are ‘red flags’ during FDA inspections and ‘denying, delaying, limiting or refusing’ a drug inspection proposed by the agency could have serious consequence, participants at a recent webinar on best practices for responding to Form 483s and warnings letters heard.